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Summary
The present study investigates the heterogeneity of graft rejection pathways in class I major histocom-
patibility complex (MHC)-disparate combinations and the susceptibility of each pathway to im-
munomodulation induced by intravenous presensitization with alloantigens . Depletion ofCD8+
T cells was induced by repeated administration of anti-CD8 monoclonal antibody. CD8+
T cell-depleted mice failed to generate anti-allo class I MHC cytotoxic T cell (CTL) responses
but exhibited anti-allo class IMHC T cell responses, such as mixed lymphocyte reaction(MLR)/
IL-2 production, that were induced by CD4+ T cells. In contrast, donor-specific intravenous
presensitization (DSP), as a model of donor-specific transfusion, induced almost complete elimi-
nation of CD4+ and CD8+ T cell-mediated MLR/11,2 production, whereas this regimen did
not affect the generation of CTL responses induced by DSP-resistant elements (CD8+ CTL
precursors and CD4+ CTL helpers) . Prolongation of skin graft survival was not induced by
either ofthe above two regimens alone, but by the combination ofthese. Prolonged graft survival
was obtained irrespective ofwhether the administration of anti-CD8 antibody capable of eliminating
CTL was started before or after DSP . The combination ofDSP with injection of anti-CD4 anti-
body also effectively prolonged graft survival . However, this was the case only when the injec-
tion of antibody was started before DSP, because such antibody administration was capable of
inhibiting the generation of CTL responses by eliminating DSP-resistant CD4+ CTL helpers.
These results indicate that (a) the graft rejection in class I-disparate combinations is induced
by CD8+ CTLinvolved and -independent pathways that are resistant and susceptible to DSP,
respectively; (b) DSP contributes to, but is not sufficient for, the prolongation of graft survival ;
and (c) the suppression of graft rejection requires an additional treatment for reducing DSP-
resistant CTL responses . The results are discussed in the context of potential clinical application
in attempts to inhibit the generation ofDSP-resistant CTL responses upon the prospective DSP.
mmune responses to alloantigens are initiated by the rec-
ognition of alloantigens byT helper (Th) cells . These Th
cells consist of multiple subsets that differ from one another
in their phenotype andmode ofalloantigen recognition (1-3) .
It has been shown that various subsets of Th cells initiate
anti-allo-immune responses, includingCTL responses, and that
allograft rejection results from complicated cellular interac-
tions, especially between T cells of different phenotypes, of
different antigen-specificities, and with distinct functions (4) .
The presentation of alloantigens via the intravenous route
positively or negatively regulates the induction of anti-allo-
immune responses as has been reported for the effect of
donor-specific transfusion (DST)' (5-15) . Earlier studies
from several laboratories have demonstrated that the reduc-
tion ofalloreactivity, as monitored by graft rejection responses,
is inducible by intravenous presensitization with cells ex-
pressing the corresponding donor alloantigens (donor-specific
intravenous presensitization [DSP]) as a model ofDST (16-20) .
This was, however, achieved in simplified donor-host combi-
nations, for example, in a donor-host combination differing
1 Abbreviations used in this paper: DSP, donor-specific intravenous presen-
sitization ; DST, donor-specific transfusion ; FMF, flow microfluorometry ;
SN, supernatants.
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DSP in conventional class I MHCdisparityfailed to produce
a beneficial effect on subsequent allograft survival (21) . To
establish themechanistic basisfor thepretransplant DST/DSP
effect, as well as to facilitate clinical application ofthis model,
it remains to be investigated which element(s) of the immune
response determines the difference in outcomes after DSP in
two types of classI MHC disparity(simplemutation vs. con-
ventional disparity). Such an investigation could provide an
approach to abrogating the DSP-resistant elements of anti-
allo-immune responses.
The present study investigated the heterogeneity of graft
rejectionpathways inducedby conventional class I MHC dis-
parity and the DSP susceptibility ofeach pathwayand/or ele-
ment ofimmune response. Theresultsdemonstrate threemajor
conclusions: First, thegraft rejection in class I-disparate com-
binations is induced by: (a) a CD8' CTLinvolved pathway
consisting of CD8' CTL precursors and allo-class I MHC-
restricted CD8' Th cells or allo-class I MHC-reactive, self
class II-restricted CD4' Th cells; and/or (b) CD8+ CTL
independent pathway(s) as detected by MLR/IL2 produc-
tion. Second, the CTITinvolved pathway generatedby CTL
precursors andallo-class IMHC-reactive, self class II-restricted
CD4' Th cells is resistant to DSP, whereas the CTL
independent pathway is susceptible to DSP. Third, theprolon-
gation of class I-disparate graft survival is achieved by the
combinationofDSPwith additional treatmentto reduce the
generation of CTL by eliminating CTL or CTL helpers.
Materials and Methods
Mice.
￿
Mouse strains used in this study are shown in Table 1.
C57BL/6 (B6), B10.BR, and B10.A mice were purchased from
Shizuoka Experimental Animal Laboratory. B6 .C-H-2bm' (bml),
B10.AKM, and B10.QBR mice were originally provided by Dr.
David Sachs (National Cancer Institute, Bethesda, MD) andbred
in our laboratory.
Intravenous Presensitization with Allogeneic Cells (Donor-specific
Presensitization). Mice were injected with 10' allogeneic spleen
cells via the intravenous route.
Media Usedfor In Vitro Cell Culturing.
￿
Culture medium used
fortheMLRwas RPMI 1640 supplemented with 10% horseserum,
5 x 10 -5 M 2-ME, sodium pyruvate, glutamine, nonessential
amino acids, and 5 mM hepes buffer. Complete medium for the
generation of CTL was prepared by replacing 10% horse serum
with 10% FCS in the above medium. RPMI 1640 supplemented
with 5% FCS plus 5 x 10 -5 M 2-ME was used for the produc-
tion of IL2 and 11,2 assays.
Monoclonal Antibodies.
￿
Anti-CD4 (GK1.5) (22) and anti-CD8
(2.43) (AmericanType CultureCollection, Rockville, MD)mAbs
were obtained from ascitic fluids of hybridomas producingthe rele-
vant antibody. Gammaglobulin fraction ofthe ascitic fluidwas ob-
tained by precipitation at 50% saturation with ammonium sulfate.
MixedLymphocyte Reaction.
￿
Theresponding lymph node cells,
obtained from apool ofthree animalspergroup, were resuspended
in complete medium and cultured at a concentration of 2 x 105
cells per culture well together with 4 x 105 irradiated (2,000 rad)
stimulating spleen cells in a total volume of 0.2 ml (16, 18, 20).
Each MLRwasperformedin triplicate in round-bottomed microcul-
ture plates (25850; CorningGlass Works, Corning, NY) andmain-
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tained in humidified atmosphere at 5% COz at 37°C. The cul-
tures were harvested at 96 h after an 8-h pulse with 20 KBq/well
of ['H]TdR by using an automatic cell harvester onto glass fiber
filters. Radioactivity was determined by liquid scintillation spec-
trometry. Results were calculated from uptake of ['H]TdR and ex-
pressed as the mean uptake in cpm ±SE of triplicate cultures.
Generation ofCytotoxic TLymphocytes.
￿
TheCTL inductionwas
performed as previously described (23). Briefly, 5 x 106 lymph
node or spleen cells were cultured in vitro with 4-10 x 105 ir-
radiated (2,000 rad) syngeneic or allogeneic spleen cells in 24-well
culture plates (25820; Corning Glass Works) in a volume of 2 ml
at 37'C for 5 d. Effector cells generated were assayed on "Cr-
labeled target cells (spleen cells cultured for 48 h with Con A at
5 p,g/ml). Percent specific lysis was calculated as described (23).
SEsin each group were <10%, and thesewere excluded from data
for simplicity.
Production ofIL2andAssaySystemfor11,2Activity.
￿
Lymphnode
cells (2 x 106/well) were cultured with 4 x 106 syngeneic or al-
logeneic stimulator spleen cells (2,000 rad) in 24-well culture plates
(25820; Corning Glass Works) in a volume of 2 ml (16, 18, 20).
After incubation at 37°C in a humidified COZ incubator (5%
COZ) for 48 h, culture supernatants (SN) were harvested by cen-
trifugation and stored at -20'C until use.
SN were assayed for IL2 activity according to their ability to
support theproliferation oftheIL2-dependentTcell line, CTLL2
(16, 18, 20). CTLL2 (10"/well) were cultured with the superna-
tant in a volume of 0.2 ml in 96-well flat-bottomed microplates
(25860; Corning Glass Works) for 24 hat 37°C. Proliferation was
assessed .by the uptake of ['H]TdR during 4-h pulsing with 20
KBq ['H]TdR/well.
Immunofluorescence Staining and Flow Microfluorometry (FMF),
The cell preparation and staining procedures were essentially the
same as described previously (24). Briefly, 106 lymphoid cells were
incubated at 4°C for 30 min with FITC-conjugated antibodies,
washed twice, resuspended, and analyzed for fluorescence. These
procedures were performed in HBSS (without phenol red) con-
taining 0.1% BSA and0.1% sodium azide. FMF analysis was per-
formed by using a FACStar® (Becton Dickinson Immunocytom-
etry Systems, Mountain View, CA). Alldata were collectedby using
log amplification, anddead cellswere rejected from analysis by ad-
ditional staining with propidium iodide.
Skin Grafting ofB6 Mice.
￿
Mice were engraftedon the flankwith
tail skin grafts accordingto an adaptation of themethod of Gilling-
ham andMedawar(25). Bandages were removedon day 7 and the
Table 1.
￿
H-2 Haplotypes of Mouse Strains Used in This Study
H-2 region
Strain
￿
K I-A I-E D
C57BL/6 (B6)
￿
b
￿
b
￿
-
￿
b
B6.C-H-26'" (bml)
￿
bml
￿
b
￿
-
￿
b
B6.C-H-2bm'z (bm12)
￿
b
￿
bm12
￿
-
￿
b
B10.BR
￿
k k k k
B10.A
￿
k k k d
B10.AKM
￿
k k k q
B10.QBR
￿
b b - qgrafts were scored daily until rejection (defined as loss of >80%
of the grafted tissue) .
Depletion ofCD8' or CD4* T Cells.
￿
The procedure was the
same as described (21, 24) . Semipurified anti-CD8 or anti-CD4
antibody was administered in vivo at the dose of 100 FAg/day three
times/wk . Administration of the antibody for 1 wk resulted in
almost complete elimination ofCD8' or CD4' T cells as revealed
by flow microfluorometric study (24) .
Results
Mediation ofClass I MHC-disparate Graft Rejection by CD8`
CTDinvolved and CD8' CTI independent Pathways. Semi-
purified anti-CD8 antibody was administered into B6 recip-
ient mice three times/wk at the dose of 100 Ag/d to elimi-
nate CD8' T cells . Intraperitoneal injection of anti-CD8
antibody for 1 wk (three treatments) resulted in almost com-
plete elimination of CD8+ T cells without affecting the
CD4' T cell subset (Fig . 1) . When this procedure was con-
tinued, the CD8' T cell-depleted state was maintained in
the recipient B6 mice until the antibody administration was
terminated (data not shown) . B6 or B10.BR recipient mice
depleted of CD8+ T cells were engrafted with skin grafts
frombm1 and B10.QBR (for B6) or from B10.A and B10.AKM
(for B10.BR) mice 1 wk after the initiation of anti-CD8 in-
jection. The skin graft survival in these four sets of class I
MHC-disparate combinations isshown in Fig. 2 . In contrast
to strikingly prolonged survival of bm1 grafts in anti-CD8
antibody-treated B6 mice (Fig. 2 A), grafts in the other three
combinations were rejected in the antibody-treated recipients
with (Fig. 2 B) or without only marginal prolongation of
survival (Fig . 2, C and D) when compared to those engrafted
in untreated recipient mice.
We examined the capacity of anti-CD8 antibody-treated
Log fluorescence Intensity
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Figure 2 .
￿
Effect of CD8+ T cell depletion on graft survival in four
combinations with class IMHC disparity. Untreated or anti-CD8-treated
B6 or B10.BR recipient mice were engrafted with skin grafts from indi-
cated strains of mice 1 wk after the initiation of the anti-CD8 treatment .
The antibody injection was continued after the skin grafting until the
grafts were rejected .
recipients to generate CTL responses as well as MLR/IIr2
production against allo-class I MHC antigens. Spleen cells
or lymph node cells from B6 or B10.BR recipient mice
receiving the anti-CD8 injection were used as responding cells
for CTL induction or MLR/IIr2 production, respectively .
The results ofFig. 3 illustrate that the administration ofanti-
CD8 antibody results in almost complete abrogation of ca-
pacities to generate anti-allo-class IMHC CTL responses in
Figure 1 . Depletion of CD8+ T
cells by in vivo administration ofanti-
CD8 antibody . Semi-purified anti-CD8
(2.43) antibodywas injected intraperito-
neally at the dose of 100 ug/day three
times/wk for 1 wk. Lymph node and
spleen cells from these antibody-treated
mice were submitted toFMF analyses.
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Figure 3 .
￿
Effect of CD8* T cell depletion on the generation ofCTL
responses in four combinations with class I MHC disparity. Spleen cells
(5 x 10 6 ) from untreated B6 or B10.BR mice or mice treated with anti-
CD8 antibody for 3 wk were cultured with irradiated stimulator cells
(106 ) from indicated strains of mice for 5 d. Effector cells generated were
assayed on Con A-induced splenicblast target cells prepared from the same
strains of mice used for the in vitro stimulation .
all four sets of class I MHC-disparate combinations. In con-
trast, reduced but still appreciable magnitudes ofMLR/IL2
production were generated by lymphoid cells from the same
CD8+ T cell-depleted mice, except in the B6-bm1 combi-
nation in which MLR and IL2 production are mediated pre-
Raspondlny calls from ntka tratied with
*&Kris
anti-COB antibody
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dominantly by CD8+ T cells (Fig. 4) . It was also shown
that MLRs generated in CD8+ T cell-depleted recipients
are mediated by CD4+ T cells (Table 2) . These results sug-
gest that the graft rejection in class I MHC-disparate combi-
nations does not necessarily require the operation of a clas-
sical CD8+ CTL pathway, but is also inducible by the
CD8+ CTLindependent pathway that is detected as CD4+
T cell-mediated MLR/IL2 production .
Prolonged Survival ofClass IMHC-disparate Grafts by Simul-
taneous Suppression of Both CD8` CTLinvolved and -indepen-
dent Pathways. An earlier study from our laboratory has re-
vealed that intravenous presensitization of B6 mice with class
I MHC-disparate bm1 cells induces the suppression of anti-
bm1 graft rejection responses, whereas such DSP in conven-
tional class I MHC-disparate combinations fails to reduce the
graft rejection potential (21) . This failure to prolong graft
survival occurred despite the suppression of anti-class IMHC
MLR/IL2 production, under conditions in which an intact
CTL response remained (21) . In a representative conventional
class I MHC-disparate combination (B6-B10.QBR), we have
confirmed the effects ofDSP on theseimmune responses . B6
mice were presensitized intravenously with 101 B10.QBR
spleen cells, and 1 wk later, lymphoid cells were tested for
their capacity to generate anti-B10.QBRMLR/IL2 produc-
tion as well as CTL responses. The results of Table 3 (Exp.
1, Group 3) and Fig . 5 (Exp. 1, Group 3) illustrate that anti-
B10.QBRMLR/IL2 production is suppressed by intravenous
presensitization, whereas this regimen does not affect the in-
duction of CTL responses . These results (Group 2) also
confirm the results obtained in Figs. 3 and 4 for the effects
of anti-CD8 administration on anti-B10.QBR immune re-
sponses . Almost complete inhibition of these immune re-
sponses was induced by the combination of DSP and anti-
CD8 (Table 3, Group 4, Exp. 1 ; and Fig. 5, Group 4, Exp. 1) .
Mice from the same groups as used in Table 3 and Fig .
5 were engrafted with B10.QBR or B6-C-H-2bm 12 (bm12)
Figure 4. Effect of CD8+ T cell
depletion on MLR/Ilr2 production in
four combinations with class I MHC
disparity. Responding lymph node cells
(2 x 105) from the same untreated
(O) or anti-CD8-treated(®) mice
as used in Fig . 3 were stimulated with
2,000 red X-irradiated spleen cells (4 x
105) from indicated strains of mice for
4 d . Vertical dotted lines inside each
column indicate [3H]TdR uptakes in
the presence of syngeneic stimulator
cells asbackground instead ofallogeneic
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stimulator cells.
A. 86 anti-bmt B . B10.BR anti-B10A
C. B10.BR anti-BMAKM D . 136 anti-B10.08R
Responding Stimulating proliferation (MLR) IL-2 production (CTLL-2 assay)
teas from ceb from 3H-TdR uptake (opm,x10-3 ) 3H-TdR uptake (cpm,xl0-3 )
136 bm1 -
MAR 810.A
8109R 810AKIM V/1W///////
as MAWMLRs were performedin the absence or presence of anti-CD4, anti-CD8, or the mixture of these. Each antibody concentration was 100 ng/ml.
t Semi-purified anti-CD8 (2.43) antibody was injected intraperitoneally at the dose of 100 ttg/d three times per week for 3 w. Lymph node cells
(2 x 105) from thoseanti-CD8-treated mice were stimulated in vitro with 2,000 rad X-irradiated indicated strains of spleen cells (4 x 105) for4 d.
s Responding cells were cultured with syngeneic spleen cells as background (Bkg).
control skin grafts 1 wk afterDSPwith B10.QBR cells. After
B10.QBR skin grafting, the administration of anti-CD8 an-
tibody was continued in Groups 2 and 4. Prolongation of
B10.QBR skin grafts was produced in the group receiving
the combined treatment (Group 4) (Fig. 6A). Such prolon-
gation was found to be specific for B10.QBR used for DSP,
since the same combined treatment did not affect the rejec-
tion of control bm12 grafts (Fig. 6 B).
Additional experiments were performed to examinetheca-
pacities offour groups ofmice to generate MLR/IIr2 produc-
tion and CTL responses 1 wk afterB10.QBR skin grafting.
The results of Table 3, Exp. 2; and Fig. 5, Exp. 2 illustrate
that these immune responses against B10.QBR are still sup-
pressed in B10.QBR skin-bearing B6 mice receivingthe com-
bined treatment(Group 4). Thus, takencollectively, theresults
Table 3.
￿
Effect ofAnti-CD8 Treatment and/or DSP on MLR in a Class I MHC-disparate Combination
' Recipient B6 mice received the DSP with B10.QBR cells 1 wk after the initiation of anti-CD8 antibody administration. Half of mice in each
groupwere submitted to MLR and IL-2 production after the DSP (Exp. 1), and the other half of mice were engrafted with B10.QBR skin grafts
1 wk after the DSP. An additional 1 wk later, these mice were used as the source of responding cells in Exp. 2.
t Responding lymph node cells were obtained 1 wk after DSP (Exp. 1) or skin grafting (Exp. 2).
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of Table 3 and Figs. 5 and 6 indicate that DSP is capable
of suppressing CD8+ CTIJuninvolved graft rejection path-
way(s) and that the inhibition of the overall class 1-disparate
graft rejection potential is inducible when the regimen for
eliminating a CD8+ CTITinvolved graft rejection element
is combined with DSP capable of abrogating CD8+ CTL
independent pathway(s).
Prolongation ofClass 1MHC-disparate Graft Survival by the
Combination of DSP with anti-CD4 Antibody Injection. We
next investigated whether the CD8+ CTLinvolved pathway
leading to graft rejection is abrogated by elimination of
CD4+ T cells. Anti-CD4 antibody was administered to B6
mice in a protocol similar to that used for anti-CD8 anti-
body. 1 wk after initiation of anti-CD4 treatment, DSPwith
B10.QBR cells was performed. Another 1 wk afterthe DSP,
Exp.
(staget) Group
Responding
a-CD8 Ab
cells from
DSP
B6"
Grafting B6
MLR
B10.QBR
IL-2
B6
production
B10.QBR
cpm x 10 -3
1 1 - - 2.9 ± 0.5 17.9 ± 2.7 0.2 ± 0.1 9.9 ± 0.1
2 + - 2.1 ± 0.3 9.3 ± 0.5 0.2 ± 0.1 4.5 ± 0.1
3 - + 2.4 ± 0.6 3.0 ± 0.7 0.2 ± 0.1 1.8 ± 0.1
4 + + 2.7 ± 1.0 3.9 ± 0.4 0.2 ± 0.0 1.1 ± 0.1
2 1 - - + 2.0 ± 0.4 23.3 ± 3.5 0.2 ± 0.0 23.1 ± 0.6
2 + - + 1.6 ± 0.1 11.4 ± 1.4 0.3 ± 0.0 11.2 ± 1.0
3 - + + 1.6 ± 0.6 3.3 ± 0.7 0.2 ± 0.0 1.5 ± 0.0
4 + + + 2.0 ± 0.3 3.2 ± 1.0 0.3 ± 0.1 1.0 ± 0.1
Table 2. CD4' T Cell Mediation ofMLR Generated in CD8+ T Cell-depleted Recipients
('H)TdR Uptake in the presence of Ab'
Responding Stimulating
cells from:t cells from: # Bkgs - Anti-CD4 Anti-CD8 Mixture
cpm x 10-)
B6 bml 3.8±0.3 6.7±0.7 2.3±0.2 4.7±0.5 1.1±0.3
B1O.BR B10.A 5.2±0.3 33.6±3 .4 6.1±0.6 27.8±5.4 4.3±0.7
B10.BR B10.AKM 5.2±0.2 22.5±2.4 3.4±0.2 22.3±3.0 3.4±0.7
B6 B10.QBR 5.3±0.2 20.6±1 .9 8.4±0.3 22.7±2.3 9.3±0.760
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Figure 5 .
￿
Effect of anti-CD8 treatment and/or DSP on CTL induction
in a class I MHC-disparate combination. Spleen cells (5 x 106) from the
same B6 mice as used in Exps . 1 and 2 of Table 3 were used as a source
ofresponding cells forCTL induction and stimulated with B10.QBR cells
(4 x 105) .
these mice were engrafted with B10.QBR grafts. The ad-
ministration of anti-CD4 or anti-CD8 antibody was con-
tinued three times/wk at the dose of 10014g/d (Fig. 7) . The
combination ofDSP with anti-CD8 injection again produced
prolongation of B10.QBR graft sunrival . The administration
of anti-CD4 antibody also induced an appreciable prolonga-
tion of B10.QBR graft survival, although this effect was
weaker than that observed for the combination ofDSP and
anti-CD8 treatment .
Time-related Diffemwe between the Effect ofCD8' and CD4+
T Cell Depletion in Combination with DSP . We finally asked
whether there are differential requirements for the effect of
CD8+ vs . CD4+ T cell depletion in combination with DSP
for reducingCTL and graft rejection responses. B6 mice were
engrafted with B10.QBR grafts 1 wk after the B10.QBR DSP,
and treatment with anti-CD4 or anti-CD8 antibody was ini-
tiated simultaneously with grafting . As shown in Fig . 8, ad-
ministration of anti-CD8 by this schedule produced prolon-
gation of B10.QBR graft survival comparable to that observed
when anti-CD8 treatment was begun 2 wk before grafting
(Figs . 6 A and 7) . In contrast, the administration of anti-
CD4 antibody initiated at the timing of grafting produced
no prolonged graft survival .
To investigate the cellular mechanisms underlying the effect
of treatment schedule on the consequences of anti-CD4 an-
tibody treatments, we examined the CTL responses of two
groups of mice in which anti-CD4 antibody administration
was started either before or after DSP . Spleen cells were ob-
tained 2 wk after DSP and tested for the presence of CD4+
T cells (Fig. 9) and for the capacity to generate anti-B10.QBR
CTL responses (Fig . 10) . These results demonstrate that : (a)
depletion ofCD4+ T cells is equally effective irrespective of
whether anti-CD4 treatment is initiated after (Group 4) or
before DSP (Group 5) (Fig . 9) ; and (b) elimination of CTL
responses by treatment with anti-CD4 antibody depends on
initiation of antibody administration before DSP. This sug-
gests that under conditions in which CD8 ` Th are elimi-
nated by DSP, anti-CD4 antibody interferes with the activa-
tion of CD8+ CTL precursors by eliminating an alternate
Th cell, CD4+ CTL helpers .
Discussion
A major issue in transplantation immunology is to ana-
lyze the cellular interactions underlying in vivo graft rejec-
tion responses . Allograft rejection results from interactions
between functionally and phenotypically distinct subsets of
alloantigen-reactive T cells (4) . Even in donor-host combi-
nations with only class IMHC disparity, the exact cellular
mechanisms remain to be clarified (vide infra) .
Another important practical goal is establishment of
manipulations by which donor-specific alloreactivity can be
abrogated. Attempts have been made to induce alloantigen-
specific unresponsiveness by introduction of alloantigens via
an intravenous route, as exemplified by the beneficial effect
ofpretransplant DST in human studies (5-10) . However, in
some cases, DST fails to reduce the recipient's alloreactivity
but rather sensitizes the host to the relevant alloantigens
(11-15) . Different outcomes ofattempts at immune modula-
tion of host reactivity have also been observed in animal studies
using DSP as a model ofDST (16-21) . Thus, it remains im-
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Figure 6 .
￿
Effect of anti-CD8 treatment and/or DSP on the generation
of graft rejection responses . B6 mice received either anti-CD8 treatment,
DSP with B10.QBR cells, or the combination of these . 1 wk after the
DSP, mice were engrafted with B10.QBR or bm12 (control) skin grafts.
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portant to identify DSP/DSTresistant elements of anti-allo
responses and to develop means to reduce these elements of
alloreactivity.
In the present study, we investigated the heterogeneity of
the cellular mechanisms of graft rejection responses in class
I MHC-disparate combinations and the effects of DSP on
each element of anti-class I MHC immune responses . The
results demonstrate that : (a) graft rejection responses in con-
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30
Figure 7 . Effect of anti-CD4/anti-CD8
treatment and/or DSP on the generation of
graft rejection responses . The protocol was es-
sentially the same as used in Table 3 and Fig.
6, except for continued injection of the same
dose of anti-CD4 antibody instead ofanti-CD8
antibody in some groups .
ventional class I MHC disparities consist of classical CD8+
CTITinvolved as well as CTITindependent pathways; (b) these
CD8+ CTLinvolved and -independent pathways are, re-
spectively, resistant and susceptible to DSP ; (c) the overall
suppression of graft rejection responses is inducible by the
combination of DSP with elimination of the CD8+ CTL
involved pathway; and (d) the reduction ofCD8+ CTL re-
sponses is achieved by eliminating either CD8+ CTL pre-
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Figure8 .
￿
Anti-CD4 treatment initiated after
DSP fails to induce the prolongation of graft
survival . B6 mice were engrafted with
B10.QBR skin grafts 1wk after the DSP with
B10.QBR cells. Simultaneously with skin
grafting, the administration of anti-CD4 or
anti-CD8 antibody was started .
Symbol Group n
Treatment of
Ab Injection
recipients with
DSP
1 6 - -
2 6 +
a-L 3 6 anti-CD4 -
o-o 4 6 anti-CDS -
--+ 5 6 anti-CD4
f-e 6 6 anti-C138
Group n
Treatment of recipients with
DSP Ab Injection
1 9 -
2 9
3 8 anti-CD4
4 9 anti-CD8Treatment with
Group antFCD4
and/orDSP
Stained with and)odir .
Log fluorescence Intensity
Figure 9.
￿
Depletion of CD4+ T cells by in vivo administration ofanti-
CD4 antibody. B6 mice were untreated (Group 1), received anti-CD4 an-
tibody 9 times for 3 wk (Group 2), received DSP alone (Group 3), re-
ceived DSP and anti-CD4 injection after DSP (three times for the final
1 wk) (Group 4), or received DSP and anti-CD4 antibody injection nine
times for 3 wk (Group 5) . Lymph node and spleen cells from these five
groups of mice were submitted to FMF analyses.
cursors/effectors or CD4+ CTL helpers . Thus, the present
study indicates the operation of heterogeneous graft rejec-
tion pathways in responses to class IMHC disparity and the
differential susceptibility of these pathways to immunomodu-
lation induced by DSP/DST.
It would be of value to summarize the cellular elements
involved in the complicated network of graft rejection re-
sponses . While CD8 + CTL have been generally regarded as
representing the major effector mechanism (26, 27), recent
studies have revealed the existence of various subsets ofTh
cells that function to activate CD8+ CTL precursors (1-3) .
These include allo class I MHC-restricted CD8+ Th cells ;
allo class I MHC-reactive self Ia-restricted CD4+ Th cells ;
and allo class II MHC-restricted CD4+ Th cells . In combi-
nations with only class I MHC disparity, the former two
Th cell subsets are activated to recognize allo class I MHC
antigens, although predominatly allo class I MHC-restricted
CD8+ Th cells function in the B6-bml combination where
class I disparity is generated by a simple mutation in a class
I MHC gene (16, 18) . In addition to this classical CD8+
CTIrinvolved pathway, it is likely that tissue destruction/graft
rejection in transplantation immunity, as well as tumor im-
munity and autoimmunity, is also induced by an alternate
immune pathway(s) (28-36) . The cellular and molecular mech-
anisms involved in such pathway(s) remain to be determined.
However, potent rejection of class I-disparate grafts in
CD8+ T cell-depleted recipients confirms the operation of
a CD8+ CTIrindependent pathway that is mediated by the
CD4+ T cell subset .
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It appears that DSP induces elimination or functional in-
activation of particular T cell subsets . Earlier studies from
our laboratory have demonstrated that DSP results in almost
complete inactivation of CD8+ Th cells but not ofCD8+
CTL precursors (18, 37) ; i .e., although the frequency of
CD8+ CTL precursors is appreciably reduced by a single
DSP (18), all precursors are not eliminated and some of these
remaining after DSP are activated to induce graft rejection
when an alternate Th cell pathway is introduced (37) . DSP
also affects some CD4+ T cells. As shown in our previous
work (21) and this study, CD4+ as well as CD8+ T cell
subpopulations as detected by MLR/Ilr2 production are sus-
ceptible to the effects ofDSP. Ofthese DSP-susceptible sub-
populations, at least the CD4+ T cell subpopulation is
capable of inducing graft rejection. This was demonstrated
by the finding presented here that the capacity of CD8+ T
cell-depleted mice to produce graft rejection was abrogated
by DSP. In contrast, a CD4+ T cell subpopulation whose
activity is monitored by the ability to assist the activation
of CTL precursors is resistant to the DSP effect . This was
also shown in the present study by demonstrating that DSP
Effector : target ratio
Figure 10 .
￿
Requirement of pre-DSP anti-CD4 treatment of reducing
the generation ofCTL responses . Spleen cells (5 x 106) from the same
five groups of mice as used in Fig . 9 were stimulated with B10.QBR
cells (106 ) .
Symbol Group
Responders from mice treated with
anti-CD4 (t ) and/or DSP ( # )
C___O
1
2
f f f f t f f f f
j
11111--" 3
i o--~ 4
f f f
f
5
t f f f f f f t fTable 4.
￿
Phenotypically and Functionally Distinct T Cell Subsets Activated by Class I MHC Alloantigens and Involved in Class I
MHC-disparate Skin Graft Rejection
capable of abrogatingthe MLR/IIr2-producing capacities of
the above CD4 + and CD8 + T cell subpopulations, in-
cluding allo class I MHC-restricted CD8+ Th cells, failed
to eliminate CTL as well as graft rejection responses. Thus,
the present study using two immunomodulating regimens
(anti-CD8 antibody treatment and DSP) may divide graft
rejection-contributing T cells into four functionally and pheno-
typically distinct subsets (See Table 4); (a) CD8' CTL
precursors, (b) CD8+ allo class I-restricted Th cells with
MLR/IIr2-producing capacities, (c) CD4+ T cells that are
not detected by MLRAL2 production but represent allo class
I-reactive self la-restricted CTLTh cells; and (d) CD4+ T
cells with MLR/IL2-producing capacities.
The present study indicates that while two of the above-
mentioned allo class I-reactive T cells (b and d) are suscep-
tible to DSP, the rest of the elements participating in CTL
responses are resistant to DSP. Therefore, it is reasonable to
assume that in class I MHC-disparate combinations, espe-
cially in which potent CTL responses are induced, DSP is
not sufficient alone to prolong graft survival, but is effective
in reducing graft rejection responses in vivo only when com-
bined with treatments eliminating either CD8' CTL
precursors or CD4+ CTLTh cells. It should be noted that
injection of anti-CD8 antibody either at the time of DSP
or at the time of grafting was effective in reducing CTL re-
sponses, whereas administration of anti-CD4 antibody was
effective for reducing the generation of CTL responses only
when it was started before DSP This is compatiblewith the
notion that the anti-CD4 antibody treatment exerts its sup-
pressive effects on the activation of CD8+ CTL precursors
by eliminating previously DSP-resistant CD4+ CTL helpers
(allo class I MHC-reactive self la-restricted) . The fact that
the administration of anti-CD4 antibody after DSP is not
effective may suggest that DSP capable of inducing concom-
itant inactivation of CD8+ Th cells sensitizes CD8+ CTL
precursors unless allo class I-reactive self la-restricted CD4+
Th cells are inactivated beforehand, and that CD8+ CTL,
once activated, function in a manner independent of CD4+
Th cells (Table 4).
The present observation that the prolongation of graft sur-
vival is induced by the combination of DSP and elimination
ofDSRresistant elements may be discussed from the following
two perspectives. First, although such combined treatment
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Participation in class I
MHC-disparate allograft rejection
Resistance
to DSP
￿
CTL-involved
￿
CTL-independent
induced the considerable or appreciable prolongation ofgraft
survival, most grafts were rejected 3-6 wk aftergrafting. The
limited term of the prolongation was also observed in our
initial studies using the B6-bm1 and B6-bm12 combinations.
Our study revealed that the survival of bml or bm12 grafts
in the DSP model was strikingly prolonged by pre-DSP
thymectomy, indicating that anti-allo tolerance once induced
by DSP is broken down by the repopulation of new clones
from the thymus (38). Thus, the limitation of graft survival
period prolongation in the present models may be explained
by the recovery of CD8' or CD4+ T cells from the thymus
under conditions in which the respective anti-CD4 or anti-
CD8 treatment is continued. Differences in the contribution
to the prolongation of graft survival between CD4' and
CD8+ T cell depletion combined with DSP could also be
accounted for by postulating differential requirements of the
thymus for repopulating T cells with different phenotypes
and functions (38-42).
Another important aspect concerns potential clinical ap-
plication of attempts to inhibit some elements ofDSRresistant
CTL responses in individuals receiving DSP. In considering
the difficulty in continuing the injection of antibody in
humans, utilization of substitutes for antibodies could be a
more practical approach for improving the DST effect. In
this context, it would be ofgreat value to mention our studies
that are currently beingperformed (Iwata, H., S. Kitagawa,
S. Sato, H. Hirose, T Hamaoka, G.M. Shearer, and H.
Fujiwara, manuscript in preparation; and Iwata, H., S.
Kitagawa, S. Sato, H. Hirose, T Hamaoka, and H. Fujiwara,
manuscript in preparation). Cyclosporin A (CsA) is a powerful
immunosuppressive drug that has been widely used in organ
transplantation in the past decade (43). This drug and a re-
cently developed drug, FK506 (44, 45), have similar func-
tional properties and alleviate allograft rejection by inhibiting
the activation ofTh cells (43, 44). Which ofthe three above-
mentioned allo-reactive Th cell subsets is the most suscep-
tible to the inhibiting effect of these drugs was examined.
We have found that the activity of allo class I MHC-reactive
self la-restricted CD4+ CTLTh cells was the most sensitive
to FK506 and that FK506 in suboptimal doses selectively
abrogated the function of this Th cell subset (Iwata, H., S.
Kitagawa, S. Sato, H. Hirose, T. Hamaoka, G.M. Shearer,
and H. Fujiwara, manuscript in preparation). Our study fur-
Phenotype Function
Capacity to
exhibit MLR
CD8 CTL-p -
CD8 CTL-Th +
CD4 CTL-Th -
CD4 Effector/inducer +ther revealed that the combination of DSP with the utiliza-
tion of suboptimal doses ofFK506 produced striking prolon-
gation of class I-disparate graft survival underconditions in
which either of these two regimens alone exhibited only a
marginal effect (Iwata, H., S. Kitagawa, S. Sato, H. Hirose,
T . Hamaoka, andH . Fujiwara, manuscript in preparation) .
Thus, these observations mayprovidean important implica-
tion for developing realistic approaches to regulate graft re-
jection responses by using suboptimal doses of immunosup-
pressive drugs.
Our present results illustrate that heterogenous graft re-
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